<DOC>
	<DOCNO>NCT00135811</DOCNO>
	<brief_summary>The FSGS Clinical Trial multi-center , prospective , control , open label randomize trial design determine treatment mycophenolate mofetil ( MMF ) conjunction pulse steroid superior treatment Cyclosporine-A ( CSA ) induce remission proteinuria 12 month .</brief_summary>
	<brief_title>Focal Segmental Glomerulosclerosis Clinical Trial ( FSGS-CT )</brief_title>
	<detailed_description>Background/Rationale . Primary FSGS lead cause end stage renal disease child adult , complete loss kidney function 50 % patient 10 year . Evidence-based treatment guideline FSGS develop lack controlled study small number patient include report . Over past decade , number study report therapeutic efficacy treatment Cyclosporine-A ( CSA ) patient nephrotic syndrome include patient steroid resistant FSGS . There two control trial treatment CSA steroid resistant FSGS , one child one adult patient . Consequently , CSA medication document efficacious control trial child adult steroid resistant FSGS . The experience mycophenolate mofetil ( MMF ) treatment patient steroid resistant FSGS limit uncontrolled trial adult patient child . Patient Population . The patient population consist child adult age 2 40 year steroid resistant FSGS . Study Design . The experimental design multi-center , prospective , control , open label randomize trial compare two treatment regimen , CSA vs. MMF/Pulse Steroids . The treatment regimens arm also include angiotensin convert enzyme inhibitor ( ACEI ) therapy alternate day low dose prednisone . The CSA MMF/Pulse steroid treatment regimen implement first 26 week randomization continue 52 week response proteinuria occur . The ACE inhibitor component continue additional 26 week withdrawal initial therapy . Logistical Structure . Participants recruit 130 participate site North America affiliate one five Core Coordinating Centers . Primary Objectives . The primary objective trial determine treatment MMF/Pulse steroids superior treatment CSA induce remission proteinuria 12 month . The main secondary objective determine treatment MMF/Pulse steroids superior treatment CSA inducing remission persist least 6 month follow withdrawal immunosuppressive therapy maintain ACEI angiotensin receptor blocker ( ARB ) therapy . Biorepository Specimens . Collection specimens biological DNA repository serve national resource ancillary study investigate pathogenesis FSGS . Duration Therapeutic Regimens Follow-up . The study treatment duration randomize patient depends level response treatment follow : 26 week neither partial complete remission occur 26-week visit ; 52 week partial complete remission 26 week 52 week , 78 week partial complete remission record 26- 52-week visit . For patient low intensity follow-up long-term assessment renal function maintain termination therapeutic regimen September , 2008 . Inclusion Criteria . - Age 2-40 year onset sign symptom FSGS , - Age ≤ 40 year randomization , - Estimated glomerular filtration rate ( GFR ) ≥ 40 ml/min/1.73 m2 , - Urine protein/creatinine ( Up/c ) &gt; 1.0 first void , - Biopsy confirm primary FSGS ( include subtypes ) , - Steroid resistance establish failure achieve sustain Up/c &lt; 1.0 follow steroid treatment course least 4 week minimum cumulative dose 56 mg/kg 1,680 mg prednisone , - Willingness follow clinical trial protocol , include medication , baseline follow-up visit procedure . Exclusion Criteria . - Secondary FSGS , - Prior therapy sirolimus , CSA , tacrolimus , MMF , azathioprin ( Imuran ) , - - Treated cytoxan , chlorambucil , levamisole , methotrexate , nitrogen mustard last 30 day , - Lactation , pregnancy , refusal birth control woman child bear potential , - Participation another therapeutic trial concurrently 30 day prior randomization , - Active/serious infection , - Malignancy , - Blood pressure &gt; 140/95 &gt; 95th percentile age/height , - Use 4 antihypertensive agent primary purpose control blood pressure , - Previously diagnose diabetes mellitus type I II ( DM I II ) , - Clinical evidence cirrhosis chronic active liver disease , - Absolute neutrophil count ( ANC ) &lt; 2000/mm3 hematocrit ( HCT ) &lt; 28 % , - History significant gastrointestinal disorder , - Organ transplantation , - Obesity ( base estimate dry weight onset disease prior steroid therapy ) define body mass index ( BMI ) &gt; 97th percentile age 2-20 year , BMI &gt; 40 kg/m2 age ≥21 year , - Allergy study medication , 17 ) Inability consent/assent . Therapeutic Regimens . CSA Arm : CSA : The initial target dose CSA 5 - 6 mg/kg per day divide two daily dos . Dosage subsequently adjust maintain 12-hour trough CSA blood concentration 100 - 250 ng/ml . CSA maintain 12 month follow randomization . MMF/Pulse Steroid Arm : MMF : The target dose MMF 25-36 mg/kg per day maximum dose 2 g/day divide two daily dos , maintain 12 month follow randomization . Dexamethasone : The target dose dexamethasone 0.9 mg/kg per dose , maximum dose 40 mg , give single dose two consecutive day start week 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 10 , 12 , 14 , 16 , 18 , 20 , 22 , 24 , 26 , 30 , 34 , 38 , 42 , 46 50 total 46 dos . Both Treatment Arms : ACEI : A maximally tolerate dose angiotensin convert enzyme inhibitor , lisinopril attempt three step two-week interval . The target maintenance dose range 0.4 mg/kg 0.6 mg/kg depend patient 's weight . Patients unable tolerate treatment ACEI previously intolerant ACEI receive angiotensin receptor blocker ( ARB ) losartan . The duration ACEI ARB therapy 18 month . Prednisone : Target dose prednisone 0.3 mg/kg per dose maximum dose 15 mg , administer single dose every day first 6 month 12-month treatment period randomization . Dose Adjustments Toxicity : Known toxicity associate therapeutic agent delineate protocol . A stepped dosage reduction protocol implement follow confirmed toxicity follow : - Step 1 : Reduce dosage 2/3 full target dose ; - Step 2 : If toxicity persist follow Step 1 , reduce dose 1/3 full target dose ; - Step 3 : If toxicity persist follow Step 2 , discontinue medication . In certain case , protocol stipulates attempt make reverse dose reduction ( follow step sequence reverse order ) follow remission toxicity . Study Visits Measurements . Main Outcome Assessment Visits : The main visit assessment study outcomes conduct baseline week 26 , 52 , 78 follow-up . These visit include 2 first-morning Up/c , full panel serum urine biochemistry measurement , complete blood count , quality life assessment ( SF-36 adult ; PedsQL child ) , complete physical examination , record medication side effect , plus additional urine , serum , plasma specimen storage repository . Whole blood DNA extraction collect onset therapy place repository consenting patient . Other Visits : In addition main outcome assessment visit baseline week 26 , 52 , 78 , first morning urine sample determination Up/c , basic blood chemistry ( BUN , creatinine , serum electrolyte glucose ) hematology MMF/Pulse Steroids arm also obtain immediately randomization , follow-up week 2 , 4 , 6 , 8 , 14 , 20 , 32 , 38 , 44 , 65 . CSA trough level , fast lipid , serum albumin , blood chemistry obtain designate subset visit . Adverse event monitoring . Adverse event , include hospitalization , modification dosage study medication record throughout follow-up period . Definition Partial Complete Remissions . At protocol assessment proteinuria , partial remission define 50 % great decline first morning Up/c mean two baseline measurement level 0.2 1.0 . A complete remission define decline Up/c level great 0.2 . Primary Outcome . The primary outcome 6-level ordinal classification base achievement remission first 52 week randomization . The least favorable outcome , designate level 6 , assign partial complete remission achieve week 2 26 , inclusive . Level 5 assign participant achieves least one partial complete remission week 2 20 , achieve either partial complete remission week 26 . By definition , primary outcome affect Up/c 26 week partial complete remission achieve 26 week , allow participant switch alternative therapy without affect primary analysis . For participant partial complete remission week 26 , score 1 4 assign depend remission status week 26 week 52 . Level 4 assign participant fail achieve either partial complete remission week 52 sustain relapse week 26 52 . Level 3 assign participant achieves partial remission week 52 . Level 2 assign participant achieves complete remission week 52 least one Up/c &gt; 0.2 week 26 week 52 . Level 1 assign participant achieves complete remission week 52 Up/c &lt; 0.2 since week 26 visit . Main Secondary Outcome . The main secondary outcome 5-level ordinal classification evaluate extent remission proteinuria persist period week 52 week 78 immunosuppressive therapy withdrawn remain ACEI ARB treatment Other Outcomes . Other outcomes include change quality life , number adverse event extra-renal complication , preservation renal function . Sample Size . The target sample size 500 patient . Primary Analysis . The primary statistical analysis compare six-level primary outcome variable randomize treatment group . The six level assign score range 1 ( favorable category ) 6 ( least favorable category ) , mean response score compare CSA MMF/Pulse steroid group within four randomization stratum define baseline estimate GFR race . The analysis carry intent-to-treat . A 2-sided test conduct 5 % significance level . Study Power . Depending remission rate control group ( classified level 1 , 2 , 3 primary outcome ) , sample size 500 randomized patient sufficient obtain 80 % power detect absolute increase remission rate 10.8 % 11.5 % MMF/Pulse Steroid CSA group .</detailed_description>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Age 240 year onset sign symptom FSGS Age ≤ 40 year time randomization ( randomization date 41st birthday ) Estimated GFR ≥ 40 ml/min/1.73 m2 recent measure prior randomization For participant &lt; age 18 year : Schwartz formula For participant ≥ age 18 year : CockroftGault formula Up/c &gt; 1.0 g protein/g creatinine first void time randomization Biopsy confirm primary FSGS ( include subtypes ) study pathologist . A minimum 1 glomerulus demonstrate segmental sclerosis light microscopy require confirm diagnosis . Steroid resistance : The participant must demonstrate steroid resistance ( defined failure achieve sustain Up/c ≤ 1.0 ) base least one treatment course high dose steroid prior randomization satisfies follow condition : minimal treatment duration 4 week minimum cumulative dose 56 mg/kg 1680 mg prednisone equivalent . In addition , participant must complete remission proteinuria ( Up/c &lt; 0.2 dipstick urine protein 0/trace ) subsequent late qualify 4week course demonstrate steroid resistance . Willingness follow clinical trial protocol , include medication , baseline followup visit procedure . Participants may take ACEI , ARB , Vitamin E , lipid lower therapy . Secondary FSGS Prior therapy sirolimus , CSA , tacrolimus , MMF , azathioprin ( Imuran ) Treated cytoxan , chlorambucil , levamisole , methotrexate , nitrogen mustard last 30 day Lactation , pregnancy , refusal birth control woman child bear potential Participation another therapeutic trial concurrently 30 day prior randomization Active/serious infection ( include , limited Hepatitis B , C , HIV ) Malignancy Blood pressure &gt; 140/95 &gt; 95th percentile age/height . Participant receive 4 antihypertensive agent primary purpose control blood pressure . Participants previously diagnose diabetes mellitus type I II : diagnosis DM I II base local criterion participant establish diagnosis . If hyperglycemia detect screening period , WHO criteria diagnosis DM I II use . Clinical evidence cirrhosis chronic active liver disease Abnormal laboratory value time study entry : Absolute neutrophil count ( ANC ) &lt; 2000/mm3 , Hematocrit ( HCT ) &lt; 28 % History significant gastrointestinal disorder , e.g , severe chronic diarrhea ( &gt; 5 watery stool per day ) active peptic ulcer disease . Organ transplantation Obesity ( base estimate dry weight onset disease prior steroid therapy ) define BMI &gt; 97th percentile age age 220 year BMI &gt; 40 kg/m2 age ≥21 year Allergy study medication Inability consent/assent Note : Participants condition meet exclusion criterion particular evaluation eligibility may reevaluate late time determine condition change entry criterion meet . In particular , blood pressure &gt; 140/95 &gt; 95th percentile age/height participant less three antihypertensive agent , participant may reevaluate eligibility add antihypertensive agent long total number agent exceed three .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Focal Segmental Glomerulosclerosis</keyword>
</DOC>